The Alzheimer’s Association International Conference in Chicago unveiled a blood test that detects early signs of Alzheimer’s with 90% accuracy, offering a less invasive alternative to spinal taps or brain scans.
Neurology professor Christoph Kleinschnitz, who attended the congress, explained in BILDplus that the test measures phosphorylated tau proteins in blood plasma, which correlate strongly with amyloid plaque buildup in the brain — a key pathological marker of Alzheimer’s disease.
This development builds on last year’s breakthrough when similar blood-based biomarkers first showed promise in detecting neurodegeneration years before clinical symptoms appear, though earlier versions lacked the precision for widespread diagnostic use.
Semaglutide shows unexpected cognitive benefits in early trials
Researchers also presented data suggesting semaglutide — a drug already approved for type 2 diabetes and obesity under brand names like Wegovy and Ozempic — may slow cognitive decline in patients with early Alzheimer’s.
Preliminary findings indicate the medication reduces brain inflammation and improves insulin signaling in neurons, potentially protecting against the metabolic dysfunction linked to Alzheimer’s progression.
Experts caution against overestimating early results
Kleinschnitz emphasized that although the blood test could revolutionize screening in primary care settings, it requires further validation across diverse populations before becoming a standalone diagnostic tool.
Similarly, semaglutide’s potential in Alzheimer’s treatment remains investigational; large-scale phase III trials are underway but will not yield conclusive results for at least two years.
How soon could these blood tests be available in doctors‘ offices?
Widespread clinical use depends on regulatory approval and standardization of testing protocols, which experts estimate could grab three to five years if validation studies continue successfully.
Is semaglutide currently prescribed for Alzheimer’s prevention?
No — the drug is not approved for Alzheimer’s treatment, and using it off-label for cognitive protection is not recommended outside of clinical trials due to insufficient evidence and potential side effects.
